Drugs / E10A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00262327 | May 2005 → Feb 2006 | neoplastic disease or syndrome | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00634595 | Mar 2008 → Dec 2010 | head and neck squamous cell carcinoma, nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E10A | “Expression of endostatin by adenoviral gene transfer (Ad-rhEndo, E10A) generates a strong systemic therapeutic effect in several models of solid tumors in mice.” NCT00262327 ↗ |
| Known as | Ad-rhEndo | “Expression of endostatin by adenoviral gene transfer (Ad-rhEndo, E10A) generates a strong systemic therapeutic effect in several models of solid tumors in mice.” NCT00262327 ↗ |
| Route | Other | “Intratumoral injections of E10A into subcutaneous xenografts of hepatocellular carcinoma BEL-7402, nasopharyngeal carcinoma CNE-2, Tongue cancer Tca8113 in nude mice...” NCT00262327 ↗ |